Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study.
Lili MaoMeiyu FangYu ChenXiaoting WeiJun CaoJing LinPeng ZhangLing ChenXiao CaoYujun ChenJun GuoLu SiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Atezolizumab in combination with bevacizumab showed promising efficacy and manageable safety in patients with advanced mucosal melanoma.
Keyphrases
- phase ii study
- open label
- locally advanced
- squamous cell carcinoma
- metastatic colorectal cancer
- ulcerative colitis
- phase ii
- clinical trial
- skin cancer
- phase iii
- rectal cancer
- small cell lung cancer
- study protocol
- radiation therapy
- basal cell carcinoma
- cross sectional
- double blind
- liver metastases
- randomized controlled trial